Skip to main content

Table 1 Baseline characteristics of cohort 1 (UKIVAS)

From: The association between ambient UVB dose and ANCA-associated vasculitis relapse and onset

Characteristics

Total

GPA

MPA

EGPA

p

n (%)

1961

1124 (57.3)

600 (30.6)

237 (12.1)

 

Age (years, median [IQR])

60 [49, 69]

58 [47, 67]

66 [57, 73]

57 [47, 65]

< 0.001

Male (%)

1017 (51.9)

610 (54.3)

280 (46.7)

127 (53.6)

0.009

Ethnicity (%)

    

< 0.001

White

1796 (91.6)

1049 (93.3)

534 (89.0)

213 (89.9)

 

Asian

85 (4.3)

44 (3.9)

34 (5.7)

7 (3.0)

 

Black

29 (1.5)

4 (0.4)

16 (2.7)

9 (3.8)

 

Mixed

9 (0.5)

5 (0.4)

3 (0.5)

1 (0.4)

 

Others

42 (2.1)

22 (2.0)

13 (2.2)

7 (3.0)

 

ANCA subtype (ELISA) (%)

    

< 0.001

PR3

499 (25.4)

437 (38.9)

53 (8.8)

9 (3.8)

 

MPO

340 (17.3)

52 (4.6)

240 (40.0)

48 (20.3)

 

ELISA-negative

63 (3.2)

21 (1.9)

15 (2.5)

27 (11.4)

 

Others

6 (0.3)

3 (0.3)

2 (0.3)

1 (0.4)

 

No ELISA recorded

1053 (53.7)

611 (54.4)

290 (48.3)

152 (64.1)

 

Latitude (degrees, median [IQR])

52.24 [51.50, 53.38]

52.40 [51.54, 53.42]

51.82 [51.46, 52.94]

52.24 [51.44, 53.48]

< 0.001

Longitude (degrees, median [IQR])

− 1.20 [− 2.23, − 0.14]

− 1.48 [− 2.36, − 0.20]

− 0.57 [− 2.00, − 0.10]

− 1.38 [− 2.20, − 0.18]

< 0.001

CW-D-UVB at symptom onset (kJ/m2, median [IQR])

83.82 [25.30, 168.57]

80.72 [25.03, 167.62]

88.40 [26.50, 167.44]

82.51 [24.50, 172.69]

0.914

Season of diagnosis (%)

    

0.891

Spring

490 (25.0)

285 (25.4)

143 (23.8)

62 (26.2)

 

Summer

527 (26.9)

307 (27.3)

161 (26.8)

59 (24.9)

 

Autumn

480 (24.5)

274 (24.4)

144 (24.0)

62 (26.2)

 

Winter

464 (23.7)

258 (23.0)

152 (25.3)

54 (22.8)

 
  1. Continuous variables are reported as mean (standard deviation (SD)) or median (interquartile range (IQR)) if not normally distributed and compared using the independent sample t-test or the Mann-Whitney U test, respectively. Categorical variables are summarised by frequency and percentage (%) and compared using the χ2 test
  2. Refer to supplementary materials for definitions of ‘date of symptom onset’ and seasons
  3. ANCA anti-neutrophil cytoplasmic antibodies, ELISA enzyme-linked immunoassay, PR3 proteinase-3, MPO myeloperoxidase, CW-DUVB cumulative-weighted UVB dose, SD standard deviation, IQR inter-quartile range